During the corresponding time, Phibro Animal Health Corporation recorded a revenue increase by 4.4 % year on year, sequentially revenue grew by 3.68 %. While revenue at the Phibro Animal Health Corporation's corporate clients
Phibro Animal Health's Comment on Sales, Marketing and Customers
Phibro Animal Health Corporation develops, manufactures, and markets products for food animals, including poultry, beef and dairy cattle, swine, aquaculture, and dogs. Its products are designed to prevent, control, and treat diseases and support nutrition to improve animal health and well-being. The company sells animal health and mineral nutrition products directly to integrated poultry, cattle, and swine producers, as well as through animal feed manufacturers, wholesalers, distributors, and veterinarians.
Phibro's Animal Health segment includes antibacterials, anticoccidials, nutritional specialty products, vaccines, vaccine adjuvants, and processing aids used in the ethanol fermentation industry. Its mineral nutrition products are intended to fortify animal diets to maintain optimal health. The company operates primarily in regions with consolidated large commercial farms, including North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East, and is investing in the companion animal sector.
Additionally, Phibro manufactures and markets ingredients for the personal care, industrial chemical, and chemical catalyst industries, selling performance products directly to customers in those sectors. In April 2024, Phibro acquired Zoetis Inc.'s medicated feed additive portfolio and related assets, which included more than 37 product lines sold in approximately 80 countries and six manufacturing sites.
News about Phibro Animal Health Corporation Contracts
Phibro Animal Health Corporation s Third Annual ESG Report Highlights Commitment to Animal Health, Nutrition, and SustainabilityPhibro Animal Health Corporation, a leading provider of animal health and nutrition solutions, is proud to release its third annual Environmental, Social, and Governance (ESG) Report, showcasing their accomplishments in 2023. The report demonstrates Phibro s dedication to optimizing animal welfare, enhancing nutrition, and promoting a sustainable world through the intricate interconnections between people, animals, and the planet.As the global focus on ESG and corporate responsibility continues to grow, Phibro recognizes the natural alignment of its business segments with these pri...
Zoetis, a leading animal health company, recently announced its decision to sell its medicated feed additive (MFA) product portfolio to Phibro Animal Health Corporation in a definitive agreement worth $350 million. The acquisition includes certain water-soluble products and related assets and is expected to be completed in the second half of the calendar year 2024. This strategic move aims to streamline Zoetis product offerings and enhance Phibro s presence in the animal health market.Zoetis, headquartered in Parsippany, New Jersey, is known for its wide range of innovative animal health solutions. Their MFA product portfolio includes additives that are mixed with animal feed to enhance nutrition, prevent d...
Phibro Animal Health’s Comment on Sales, Marketing and Customers
Phibro Animal Health Corporation develops, manufactures, and markets products for food animals, including poultry, beef and dairy cattle, swine, aquaculture, and dogs. Its products are designed to prevent, control, and treat diseases and support nutrition to improve animal health and well-being. The company sells animal health and mineral nutrition products directly to integrated poultry, cattle, and swine producers, as well as through animal feed manufacturers, wholesalers, distributors, and veterinarians.
Phibro's Animal Health segment includes antibacterials, anticoccidials, nutritional specialty products, vaccines, vaccine adjuvants, and processing aids used in the ethanol fermentation industry. Its mineral nutrition products are intended to fortify animal diets to maintain optimal health. The company operates primarily in regions with consolidated large commercial farms, including North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East, and is investing in the companion animal sector.
Additionally, Phibro manufactures and markets ingredients for the personal care, industrial chemical, and chemical catalyst industries, selling performance products directly to customers in those sectors. In April 2024, Phibro acquired Zoetis Inc.'s medicated feed additive portfolio and related assets, which included more than 37 product lines sold in approximately 80 countries and six manufacturing sites.
Sources:
Phibro Animal Health Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Phibro Animal Health Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Phibro Animal Health Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
204.34 %